Diagnostic and prognostic molecular markers in common adult gliomas

References

• Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol.61(3), 215–225 (2002).
   PubMed Web of Science ®Google Scholar
• Scott CB, Scarantino C, Urtasun R et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int. J. Radiat. Oncol. Biol. Phys.40(1), 51–55 (1998).
   PubMed Web of Science ®Google Scholar
• Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol.15(4), 1294–1301 (1997).
   PubMed Web of Science ®Google Scholar
• Pignatti F, Van Den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol.20(8), 2076–2084 (2002).
   PubMed Web of Science ®Google Scholar
• Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology69(13), 1366–1373 (2007).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Di Patre Pl, Burkhard C et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol.108(1), 49–56 (2004).
   PubMed Web of Science ®Google Scholar
• Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of tp53 mutations and p53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin. Cancer Res.8(5), 1117–1124 (2002).
   PubMedGoogle Scholar
• Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int. J. Cancer53(4), 550–555 (1993).
   PubMed Web of Science ®Google Scholar
• Jaros E, Perry RH, Adam L et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br. J. Cancer66(2), 373–385 (1992).
   PubMed Web of Science ®Google Scholar
• Johannessen AL, Torp SH. The clinical value of Ki-67/mib-1 labeling index in human astrocytomas. Pathol. Oncol. Res.12(3), 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res.64(19), 6892–6899 (2004).
   PubMed Web of Science ®Google Scholar
• Perry A, Jenkins RB, O’Fallon JR et al. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer86(4), 672–683 (1999).
   PubMed Web of Science ®Google Scholar
• Tortosa A, Vinolas N, Villa S et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer97(4), 1063–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Jarvela S, Helin H, Haapasalo J et al. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol. Appl. Neurobiol.32(4), 441–450 (2006).
   PubMedGoogle Scholar
• Aldape KD, Ballman K, Furth A et al. Immunohistochemical detection of egfrvIIi in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol.63(7), 700–707 (2004).
   PubMed Web of Science ®Google Scholar
• Liu L, Backlund Lm, Nilsson BR et al. Clinical significance of egfr amplification and the aberrant egfrvIIi transcript in conventionally treated astrocytic gliomas. J. Mol. Med.83(11), 917–926 (2005).
   PubMed Web of Science ®Google Scholar
• Smith JS, Tachibana I, Passe SM et al. PTEN mutation, egfr amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst.93(16), 1246–1256 (2001).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi Me, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Scherer H. Cerebral astrocytoma and their derivatives. Am. J. Cancer40, 159–198 (1940).
   Google Scholar
• Von Deimling A, Von Ammon K, Schoenfeld D, Wiestler Od, Seizinger Br, Louis Dn. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol.3(1), 19–26 (1993).
   PubMed Web of Science ®Google Scholar
• Filippini G, Falcone C, Boiardi A et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro. Oncol.10(1), 79–87 (2007).
   PubMedGoogle Scholar
• Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br. J. Neurosurg.21(5), 496–500 (2007).
   PubMed Web of Science ®Google Scholar
• Curran WJ JR, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J. Natl Cancer Inst.85(9), 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Seiferheld W, Scott C et al. Reexamining the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. Int. J. Radiat. Oncol. Biol. Phys.57(2 Suppl), S135–S136 (2003).
   Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343(19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Rivera Al, Pelloski CE, Gilbert MR et al.MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro. Oncol.12(2), 116–121
   PubMedGoogle Scholar
• Cairns-Smith S, Karran P. Epigenetic silencing of the DNA repair enzyme o6-methylguanine-DNA methyltransferase in mex-human cells. Cancer Res.52(19), 5257–5263 (1992).
   PubMedGoogle Scholar
• Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF. Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J. Biol. Chem.271(23), 13916–13924 (1996).
   PubMed Web of Science ®Google Scholar
• Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.)6(8), 1079–1099 (2007).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al.MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol.26(13), 2192–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol.27(8), 1275–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Ozawa T, Hirose Y et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res.61(13), 4956–4960 (2001).
   PubMed Web of Science ®Google Scholar
• Mischel PS, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene22(15), 2361–2373 (2003).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res.12(2), 107–112 (2000).
   PubMedGoogle Scholar
• Kleihues P BP, Collins VP, Newcomb EW, Ohgaki H, Cavenee Wk. Glioblastoma. In: Pathology and Genetics of Tumours of the Nervous System. Kleihues P (Eds). International Agency for Research on Cancer (IARC) Press, Lyon, France 29–39 (2000).
   Google Scholar
• Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res.63(20), 6962–6970 (2003).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem.273(1), 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem.273(5), 2817–2822 (1998).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl Wl. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J. Biol. Chem.270(51), 30562–30566 (1995).
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Thykjaer T, Orntoft TF, Damstrup L, Poulsen HS. Profile of differentially expressed genes mediated by the type III epidermal growth factor receptor mutation expressed in a small-cell lung cancer cell line. Br. J. Cancer85(8), 1211–1218 (2001).
   PubMed Web of Science ®Google Scholar
• Zhan Y, O’rourke DM. Shp-2-dependent mitogen-activated protein kinase activation regulates egfrvIIi but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res.64(22), 8292–8298 (2004).
   PubMedGoogle Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to egfr kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res.61(3), 1122–1128 (2001).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D et al. Prognostic effect of epidermal growth factor receptor and egfrvIIi in glioblastoma multiforme patients. Clin. Cancer Res.11(4), 1462–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Ballman KV, Furth AF et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol.25(16), 2288–2294 (2007).
   PubMed Web of Science ®Google Scholar
• Tuzi NL, Venter DJ, Kumar S, Staddon SL, Lemoine NR, Gullick WJ. Expression of growth factor receptors in human brain tumours. Br. J. Cancer63(2), 227–233 (1991).
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res.61(18), 6674–6678 (2001).
   PubMedGoogle Scholar
• Schlegel J, Piontek G, Budde B, Neff F, Kraus A. The akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme. Cancer Lett.158(1), 103–108 (2000).
   PubMedGoogle Scholar
• Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res.20(4), 2761–2771 (2000).
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Zhai G, Suzuki Y et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol.22(10), 1926–1933 (2004).
   PubMed Web of Science ®Google Scholar
• Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3´-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res.63(11), 2742–2746 (2003).
   PubMed Web of Science ®Google Scholar
• Mawrin C, Diete S, Treuheit T et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int. J. Oncol.23(3), 641–648 (2003).
   PubMedGoogle Scholar
• Cho HN, Lee YJ, Cho CK, Lee SJ, Lee YS. Downregulation of ERK2 is essential for the inhibition of radiation-induced cell death in HSP25 overexpressed L929 cells. Cell Death Differ.9(4), 448–456 (2002).
   PubMedGoogle Scholar
• Belka C, Knippers P, Rudner J, Faltin H, Bamberg M, Budach W. MEK1 and ERK1/2 kinases as targets for the modulation of radiation responses. Anticancer Res.20(5A), 3243–3249 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Bakanauskas VJ, Cerniglia GJ et al. The ras radiation resistance pathway. Cancer Res.61(10), 4278–4282 (2001).
   PubMed Web of Science ®Google Scholar
• Jalal Hosseinimehr S, Inanami O, Hamasu T et al. Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in hl60 cells. J. Radiat. Res. (Tokyo)45(4), 557–561 (2004).
   PubMed Web of Science ®Google Scholar
• Mori K, Tani M, Kamata K et al. Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells. Free Radic. Res.33(2), 157–166 (2000).
   PubMed Web of Science ®Google Scholar
• Brown CK, Khodarev NN, YU J et al. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett.565(1–3), 167–170 (2004).
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Lin E, Zhang L et al. Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma. Clin. Cancer Res.12(13), 3935–3941 (2006).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/akt, and glioma response to erlotinib. J. Natl Cancer Inst.97(12), 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer22(1), 9–15 (1998).
   PubMedGoogle Scholar
• Karlbom AE, James CD, Boethius J et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum. Genet.92(2), 169–174 (1993).
   PubMed Web of Science ®Google Scholar
• Fujisawa H, Reis RM, Nakamura M et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Invest.80(1), 65–72 (2000).
   PubMed Web of Science ®Google Scholar
• Homma T, Fukushima T, Vaccarella S et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol.65(9), 846–854 (2006).
   PubMed Web of Science ®Google Scholar
• Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res.62(15), 4364–4368 (2002).
   PubMed Web of Science ®Google Scholar
• Shostak K, Labunskyy V, Dmitrenko V et al. Hc gp-39 gene is upregulated in glioblastomas. Cancer Lett.198(2), 203–210 (2003).
   PubMed Web of Science ®Google Scholar
• Markert JM, Fuller CM, Gillespie GY et al. Differential gene expression profiling in human brain tumors. Physiol. Genomics5(1), 21–33 (2001).
   PubMedGoogle Scholar
• Lal A, Lash AE, Altschul SF et al. A public database for gene expression in human cancers. Cancer Res.59(21), 5403–5407 (1999).
   PubMed Web of Science ®Google Scholar
• Nigro JM, Misra A, Zhang L et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res.65(5), 1678–1686 (2005).
   PubMed Web of Science ®Google Scholar
• Tso CL, Freije WA, Day A et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res.66(1), 159–167 (2006).
   PubMed Web of Science ®Google Scholar
• Colin C, Baeza N, Bartoli C et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene25(19), 2818–2826 (2006).
   PubMed Web of Science ®Google Scholar
• Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-a. Biochem. J.380(Pt 3), 651–659 (2004).
   PubMed Web of Science ®Google Scholar
• Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (hc-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem. J.365(Pt 1), 119–126 (2002).
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Mahajan A, Maor M et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res.11(9), 3326–3334 (2005).
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev.15(2), 194–202 (2006).
   PubMed Web of Science ®Google Scholar
• Shinojima N, Kochi M, Hamada J et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J. Neurosurg.101(2), 219–226 (2004).
   PubMedGoogle Scholar
• Senger D, Cairncross JG, Forsyth PA. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J.9(3), 214–221 (2003).
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain130(Pt 10), 2596–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Burton EC, Lamborn KR, Forsyth P et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin. Cancer Res.8(1), 180–187 (2002).
   PubMedGoogle Scholar
• Burton EC, Lamborn KR, Feuerstein BG et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res.62(21), 6205–6210 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell9(3), 157–173 (2006).
   PubMed Web of Science ®Google Scholar
• Tso CL, Shintaku P, Chen J et al. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res.4(9), 607–619 (2006).
   PubMedGoogle Scholar
• Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res.64(18), 6503–6510 (2004).
   PubMed Web of Science ®Google Scholar
• Han SJ, Yang I, Otero JJ et al. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J. Neurosurg.112(5), 990–996 (2010).
   PubMed Web of Science ®Google Scholar
• Beaumont TL, Kupsky WJ, Barger GR, Sloan AE. Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J. Neurooncol.83(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol.15(6), 740–746 (2003).
   PubMed Web of Science ®Google Scholar
• Colman H, Zhang L, Sulman EP et al. A multigene predictor of outcome in glioblastoma. Neuro. Oncol.12(1), 49–57 (2010).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol.23(4), 360–364 (1988).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery31(1), 78–82 (1992).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12(10), 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90(19), 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol.24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• Van Den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european organisation for research and treatment of cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Griffin CA, Burger P, Morsberger L et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol.65(10), 988–994 (2006).
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KY et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res.66(20), 9852–9861 (2006).
   PubMed Web of Science ®Google Scholar
• Kuo LT, Kuo KT, Lee MJ et al. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int. J. Cancer124(12), 2872–2879 (2009).
   PubMedGoogle Scholar
• Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer113(3), 379–385 (2005).
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol.116(6), 597–602 (2008).
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol.11(4), 341–347 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science324(5924), 261–265 (2009).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455(7216), 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Bredel M, Scholtens DM, Harsh GR et al. A network model of a cooperative genetic landscape in brain tumors. JAMA302(3), 261–275 (2009).
   PubMedGoogle Scholar
• Li A, Walling J, Ahn S et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res.69(5), 2091–2099 (2009).
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, egfr, and NF1. Cancer Cell17(1), 98–110 (2010).
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Batchelor TT, Zhang WT et al. A “Vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res.69(13), 5296–5300 (2009).
   PubMed Web of Science ®Google Scholar
• Ananthnarayan S, Bahng J, Roring J et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J. Neurooncol.88(3), 339–347 (2008).
   PubMedGoogle Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar